Item 7.01 Regulation FD Disclosure.
On January 13, 2022, Adagio Therapeutics, Inc. (the “Company”) intends to make a
presentation at the J.P. Morgan Healthcare Conference, a copy of which can be
found on the Company’s website at
https://investors.adagiotx.com/news-events/events-presentations and is
incorporated herein by reference.
The information in this Item 7.01 is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed incorporated by reference in any filing made by
the Company under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On January 12, 2022, the Company issued a press release entitled “Adagio
Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants
and Outlines Initiatives to Address Omicron.” The full text of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release, dated January 12, 2022. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses